{'fraction_non_alphanumeric': 0.022878228782287822, 'fraction_numerical': 0.016974169741697416, 'mean_word_length': 5.0, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Effects of Vitis coignetiae on the Quality and Antihypertension of Vitis hybrid Red Wine

The goal of this study was to develop a high value Korean red wine possessing antihypertension activity. The effects of some medicinal plants and grapes on the alcohol fermentation process and the angiotensin I-converting enzyme (ACE) inhibitory activity of Vitis hybrid red wine were investigated. Various Vitis hybrid red wines were vinified by the fermentation of a mixture of Vitis hybrid must and some medicinal plants and grapes at 25 o C for 10 days. Of these red wines, the Vitis hybrid–Vitis coignetiae red wine exhibited a high ethanol content of 12.0% and had a good level of acceptability. It also showed a high antihypertensive ACE inhibitory activity of 68.5%. After post-fermentation of 60 days, the ACE inhibitory activities of the Vitis hybrid–Vitis coignetiae red wine exhibited the highest ACE inhibitory activity of 80.7% (IC50: 28 mg/mL) and also had the best acceptability. The C18 solid phase extracts of the Vitis hybrid–Vitis coignetiae red wine, after 60 days post-fermentation, showed clear antihypertensive effects on spontaneously hypertensive rats. Our results reveal that the Vitis hybrid–Vitis coignetiae red wine has the potential to become a new functional red wine due to its good acceptability and high antihypertensive activity.